Biotech
SaludOnNet Accelerates in the Wake of the Pandemic: Forecasts a Turnover of 12 Million in 2021
The health portal based on payment for use of medical services SaludOnNet billed $6.6 million (€5.4 million) in 2020 as a result of a stabilization policy. With an eye on the long term, the platform plans to initiate a growth plan abroad by 2022. The areas where the expansion project will be carried out are Latin America, the state of Florida in North America, and the United Kingdom
SaludOnNet, a technology platform focused on the pay-per-use of specific medical services, used by 250,000 patients, expects to bill $14.6 million (€12 million) in 2021. These figures would mean recovering pre-pandemic numbers, after a period of “stabilization”, according to the company.
The company is essentially targeting the sector of the population that does not have private health insurance, estimated at 80% in the case of Spain. The aim of SaludOnNet is to offer an alternative to public healthcare by contracting specific services on a pay-per-use basis.
At the moment, the app developed by the company offers more than 40,000 services and has a portfolio of more than 3,200 private clinics and hospitals in Spain.
Read more details about the company SaludOnNet and its plans to expand its business abroad with our companion app. The Born2Invest mobile app brings you the latest business news in the world so you can stay on top of the market.
SaludOnNet plans to record a profit of up to $3.65 million (€3 million) in 2020
SaludOnNet, founded in 2016 and with an initial investment of half a million euros, had doubled sales every year since its birth until last year. Despite this positive dynamic, the trajectory was cut short with the irruption of Covid-19 in 2020, a period in which the company turned over $6.6 million (€5.4 million).
Even so, the forecast for 2021 is positive. With the company immersed in a context of stabilization derived from the coronavirus crisis, its intention is to exceed the growth rate prior to Covid-19, as reported to PlantaDoce by Guillermo Prieto, CEO of SaludOnNet.
In this sense, and with a view to this year, the company plans to record a profit of up to three million euros. These expectations have opened the door to a growth in the workforce over the last year. In this sense, the company has increased its number of employees by ten.
The platform plans to initiate a growth plan abroad by 2022
With an eye on the long term, the platform plans to initiate a growth plan abroad by 2022. The areas where the expansion project will be carried out are Latin America, the state of Florida in North America, and the United Kingdom. As part of this growth strategy, SaludOnNet also intends to expand its portfolio of services related to other areas such as wellness, aesthetics, dental medicine, and sports medicine.
__
(Featured image by Glenn Carstens-Peters via Unsplash)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
-
Fintech2 weeks ago
‘Mastercard for Fintechs’ the Program Which Offers Support to the Most Innovative Startups
-
Cannabis5 days ago
Ukraine Reveals List of Diseases that Qualify for Medical Cannabis Treatment
-
Crowdfunding1 week ago
Nuvola Zero Launches an Equity Crowdfunding to Raise 1.5 Million Euros on Mamacrowd
-
Crowdfunding3 days ago
The Third Edition of Funds TOgether, UniTo’s Crowdfunding Initiative, Is Underway